Background: Stroke and AD patients with gut complications often present worsened neurological outcomes. The goal of this study was to examine the role of extracellular vesicle (EV)-mediated pyroptosis in the bi-directional gut-brain axis after photothrombotic stroke (PTS) in aged 3xTg mice and wildtype (WT) controls.
Method: Twelve-month 3xTg and WT male and female mice underwent PTS using a YAG laser. Lesion volume analysis was performed at 1-month post-PTS. At 24 hours after PTS, intestinal and cortical tissue was collected for Western Blot analysis for the following inflammasome proteins: caspase-1, apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), interleukin-1b, and Gasdermin-D (GSDMD). Additionally, brain and intestines were sectioned for immunohistochemical analysis of GSDMD and Amyloid-Beta (Ab). In order to show changes in gut function, gut permeability was measured 72 hours post PTS using a FITC-dextran assay. Moreover, we performed an adoptive transfer in which stool-derived EVs collected from 3xTg- PTS and WT-PTS mice were injected into naïve 3xTg and WT mice. Cortical lysates were examined for expression of inflammasome proteins, GSDMD, and Ab using Western Blot analysis.
Results: 3xTg mice presented increased infarct volume compared to WT-PTS mice one month after PTS. Based on Western blot analysis, we found that inflammasome proteins, GSDMD, and Ab were significantly increased in both intestinal and cortical tissue in 3xTg- PTS mice compared to WT- PTS mice at 24 hours post-stroke. Results from the FITC-Dextran assay showed that gut permeability was significantly increased in the aged 3xTg-PTS mice compared to WT- PTS mice 72 hours post-PTS. Additionally, our immunohistochemical analysis in both WT and 3xTg PTS mice presented evidence of activated/ameboid microglial morphology as well as the presence of GSDMD and Ab in the brain and intestines 72 hours after stroke. Lastly, we demonstrated increased levels of inflammasome proteins, GSDMD, and Ab after adoptive transfer.
Conclusion: Taken together these results indicate an important role for EV signaling and pyroptosis in disruption of the bidirectional gut-brain axis after stroke in aged 3xTg mice in an animal model of stroke.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/alz.089237 | DOI Listing |
Alzheimers Dement
December 2024
Laboratory of Neuroscience (LIM27), Departamento e Instituto de Psiquiatria, Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo, São Paulo, São Paulo, Brazil.
Background: Nearly all individuals with Alzheimer's disease (AD) develop neuropsychiatric symptoms (NPS). Lithium is a mood-stabilizer and is efficient in reducing disruptive behaviors in bipolar-disorder; this characteristic could be an opportunity to investigate the use of lithium in treating behavioral changes in AD.
Method: We tested lithium carbonate treatment in 3xTg-AD and age-matched Wild-type male mice (CEUA/PROCESS: 1605/2020; 4127240122).
Alzheimers Dement
December 2024
University of Miami, Miami, FL, USA.
Background: Exposures to hazardous noise causes irreversible injury to the structures of the inner ear, leading to changes in hearing and balance function with strong links to age-related cognitive impairment. While the role of noise-induced hearing loss in long-term health consequences, such as progression or development of Alzheimer's Disease (AD) has been suggested, the underlying mechanisms and behavioral and cognitive outcomes or therapeutic solutions to mitigate these changes remain understudied. This study aimed to characterize the association between blast exposure, hearing loss, and the progression of AD pathology, and determine the underlying mechanisms.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
University of Texas Medical Branch, Galveston, TX, USA.
Background: Rodent models have been proved pivotal in Alzheimer's disease (AD) research. Nevertheless, the use of models that only recapitulate one aspect of AD neuropathology, and of early time points that might be excluding important features such as age-dependent inflammation and senescence, could hinder the development of effective AD therapeutics. Several tau immunotherapies are currently undergoing clinical trial.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Institute for Memory Impairments and Neurological Disorders (MIND), Irvine, CA, USA.
Background: Late-onset Alzheimer's disease (LOAD) represents the majority of human AD cases, yet the availability of animal models that accurately reflect LOAD progression and pathology is limited. Traditional transgenic mouse models including 3xTg-AD and 5xFAD rely on supraphysiological overexpression of familial AD risk genes, failing to adequately replicate the disease progression observed in LOAD. Here, we present the first characterization of MODEL-AD1 (MAD1), a platform mouse developed by the Model Organism Development and Evaluation for Late-onset Alzheimer's Disease (MODEL-AD) Consortium.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
University of Western Ontario, London, ON, Canada.
Background: Ambroxol is an expectorant under study as a treatment for synucleinopathies, such as Parkinson's disease. It is a pharmacological chaperone of the lysosomal enzyme β-glucocerebrosidase (GCase), increasing this enzyme and subsequently reducing accumulation of alpha-synuclein. Although the mechanism of enhanced clearance is not fully understood, ambroxol stimulates lysosomal function through activation of transcription factor EB (TFEB), which drives hundreds of lysosomal genes.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!